Posted by Michael Wonder on 06 Nov 2018
Seattle Genetics submits supplemental biologics license application for Adcetris (brentuximab vedotin) in front-line treatment of CD30 expressing peripheral T-cell lymphomas
5 November 2018 - Submission based on positive Phase 3 ECHELON-2 trial evaluating Adcetris in frontline CD30-expressing peripheral T-cell lymphoma.
Seattle Genetics announced today that it has submitted a supplemental biologics license application to the U.S. FDA based on data from the phase 3 ECHELON-2 trial evaluating Adcetris (brentuximab vedotin) in combination with chemotherapy for the frontline treatment of patients with CD30-expressing peripheral T-cell lymphoma.
The positive topline results of the phase 3 ECHELON-2 clinical trial were announced in October 2018 and full data will be presented at the upcoming American Society of Hematology Annual Meeting, December 1-4, 2018 in San Diego, Calif.
